Notifications
Back
Technology
Technology
FNCT BIOTECH is 

advancing a novel antibody-based therapy for pulmonary fibrosis, a disease with significant unmet medical needs. With proof of concept (PoC) established and a clearly defined mechanism of action (MoA), our treatment candidate has demonstrated strong therapeutic potential. Upon successful development, it is poised to become a game changer in pulmonary fibrosis care, offering substantial clinical impact and commercial value. 


"Once fully developed, it is expected to revolutionize pulmonary fibrosis care, delivering significant clinical benefits and strong commercial potential." 

Mode of Action of FB-101
The current paradigm of fibrosis mechanism
  • TGF-β, a widely recognized key regulator of fibrosis, is a primary target in developing antifibrotic therapies
  • For these reasons, various molecules that mediate downstream signaling of TGF-β have also emerged as important targets for anti-fibrotic drug development.

※ Click on the image to enlarge.

「 FB-101」

Reversible treatment effect on fibrosis

FNCT Biotech’s paradigm
  • CSF3 is the upstream pathway that regulates all the pivotal fibrosis pathways. 
  • regulates the TGF-β pathway and modulates myofibrogenesis and ECM deposition through reciprocal cooperation with TGF-β. 
  • promotes ECM accumulation by stabilizing collagen through the upregulation of prolyl-hydroxylase. 
  • A positive feedback loop between CSF3 and TGF-β1 plays a significant role in the progression of idiopathic pulmonary fibrosis.
FNCT BIOTECH is 

advancing a novel antibody-based therapy for pulmonary fibrosis, a disease with significant unmet medical needs. With proof of concept (PoC) established and a clearly defined mechanism of action (MoA), our treatment candidate has demonstrated strong therapeutic potential. Upon successful development, it is poised to become a game changer in pulmonary fibrosis care, offering substantial clinical impact and commercial value. 


"Once fully developed, it is expected to revolutionize pulmonary fibrosis care, delivering significant clinical benefits and strong commercial potential." 

Mode of Action of FB-101
The current paradigm of fibrosis mechanism
  • TGF-β, a widely recognized key regulator of fibrosis, is a primary target in developing antifibrotic therapies 
  • For these reasons, various molecules that mediate downstream signaling of TGF-β have also emerged as important targets for anti-fibrotic drug development.
FNCT Biotech’s paradigm
  • CSF3 is the upstream pathway that regulates all the pivotal fibrosis pathways. 
  • regulates the TGF-β pathway and modulates myofibrogenesis and ECM deposition through reciprocal cooperation with TGF-β. 
  • promotes ECM accumulation by stabilizing collagen through the upregulation of prolyl-hydroxylase. 
  • A positive feedback loop between CSF3 and TGF-β1 plays a significant role in the progression of idiopathic pulmonary fibrosis.

「 FB-101」

Reversible treatment effect on fibrosis

Fnct Biotech logo

E-mail

fnct@fnctbiotech.com

Headquarter

City Office Tower Rm 710, 411 Yanghyeon-ro, Jungwon-gu, Seongnam-si, Gyeonggi-do, Republic of Korea

R&D Center

Chungmuro New Building Rm 226, 2 Toegye-ro 36-gil, Jung-gu, Seoul, Republic of Korea

Copyright ⓒ FNCT BIOTECH All Rights Reserved.

Fnct Biotech logo

E-mail

fnct@fnctbiotech.com

Headquarter
City Office Tower Rm 710, 411 Yanghyeon-ro, Jungwon-gu, Seongnam-si, Gyeonggi-do, Republic of Korea
R&D Center
Chungmuro New Building Rm 226, 2 Toegye-ro 36-gil, Jung-gu, Seoul, Republic of Korea

Copyright ⓒ FNCT BIOTECH All Rights Reserved.